Cardiol Therapeutics Inc. ( (CRDL) ) has released its Q1 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead product CardiolRx™ in clinical development. The latest earnings report for the three months ended March 31, 2025, shows a net loss of $8.29 million, a slight improvement from the $9.18 million loss in the same period last year. The company reported a decrease in cash and cash equivalents to $23.29 million from $30.58 million at the end of 2024. Key financial metrics include operating expenses of $8.43 million and interest income of $248,269. Despite the losses, Cardiol continues to advance its clinical programs, including the Phase III MAVERIC trial for recurrent pericarditis and the development of CRD-38 for heart failure. Looking ahead, Cardiol’s management remains focused on advancing its clinical trials and exploring potential partnerships to support commercialization efforts.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue